{"id":5588,"date":"2021-12-23T16:28:59","date_gmt":"2021-12-23T16:28:59","guid":{"rendered":"https:\/\/www.sicklecelldisease.org\/?p=5588"},"modified":"2021-12-29T21:05:39","modified_gmt":"2021-12-29T21:05:39","slug":"scdaa-news-advisory-partial-hold-on-gene-therapy-trial","status":"publish","type":"post","link":"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/","title":{"rendered":"SCDAA News Advisory: Partial Hold on Gene Therapy Trial"},"content":{"rendered":"<p>On December 20, the FDA placed a partial hold on bluebird bio\u2019s clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy, temporarily stopping testing on study volunteers under age 18. This partial hold was a response to the investigation of one adolescent with sickle cell disease who has persistent anemia (not dependent on transfusion) a year and a half following treatment. <a href=\"https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-announces-partial-clinical-hold-patients-under-18\">Read more<\/a>.<\/p>\n<p>Adults can continue enrollment and treatment in bluebird bio studies. Other clinical research studies of gene therapy for sickle cell disease are continuing.<\/p>\n<p>The clinical research process has many built-in safety precautions, which include the partial hold implemented by the FDA. MARAC will continue to monitor the situation closely on behalf of the individuals and families living with sickle cell disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On December 20, the FDA placed a partial hold on bluebird bio\u2019s clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy, temporarily stopping testing on study volunteers under age 18. This partial hold was a response to the investigation of one adolescent with sickle cell disease who has persistent anemia (not dependent on transfusion) a year [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-5588","post","type-post","status-publish","format-standard","hentry","category-marac-statement"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>SCDAA News Advisory: Partial Hold on Gene Therapy Trial - Sickle Cell Disease Association of America Inc.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SCDAA News Advisory: Partial Hold on Gene Therapy Trial - Sickle Cell Disease Association of America Inc.\" \/>\n<meta property=\"og:description\" content=\"On December 20, the FDA placed a partial hold on bluebird bio\u2019s clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy, temporarily stopping testing on study volunteers under age 18. This partial hold was a response to the investigation of one adolescent with sickle cell disease who has persistent anemia (not dependent on transfusion) a year [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Sickle Cell Disease Association of America Inc.\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-23T16:28:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-29T21:05:39+00:00\" \/>\n<meta name=\"author\" content=\"Emma Day\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emma Day\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/\",\"url\":\"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/\",\"name\":\"SCDAA News Advisory: Partial Hold on Gene Therapy Trial - Sickle Cell Disease Association of America Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/#website\"},\"datePublished\":\"2021-12-23T16:28:59+00:00\",\"dateModified\":\"2021-12-29T21:05:39+00:00\",\"author\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/22ff615054be6fdd3e861004652dd8e3\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sicklecelldisease.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SCDAA News Advisory: Partial Hold on Gene Therapy Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#website\",\"url\":\"https:\/\/www.sicklecelldisease.org\/\",\"name\":\"Sickle Cell Disease Association of America Inc.\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sicklecelldisease.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/22ff615054be6fdd3e861004652dd8e3\",\"name\":\"Emma Day\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/61d0c1099d251a9cdc20252cca50e230?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/61d0c1099d251a9cdc20252cca50e230?s=96&d=mm&r=g\",\"caption\":\"Emma Day\"},\"url\":\"https:\/\/www.sicklecelldisease.org\/author\/emma\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SCDAA News Advisory: Partial Hold on Gene Therapy Trial - Sickle Cell Disease Association of America Inc.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/","og_locale":"en_US","og_type":"article","og_title":"SCDAA News Advisory: Partial Hold on Gene Therapy Trial - Sickle Cell Disease Association of America Inc.","og_description":"On December 20, the FDA placed a partial hold on bluebird bio\u2019s clinical program for lovotibeglogene autotemcel (lovo-cel) gene therapy, temporarily stopping testing on study volunteers under age 18. This partial hold was a response to the investigation of one adolescent with sickle cell disease who has persistent anemia (not dependent on transfusion) a year [&hellip;]","og_url":"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/","og_site_name":"Sickle Cell Disease Association of America Inc.","article_published_time":"2021-12-23T16:28:59+00:00","article_modified_time":"2021-12-29T21:05:39+00:00","author":"Emma Day","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Emma Day","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/","url":"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/","name":"SCDAA News Advisory: Partial Hold on Gene Therapy Trial - Sickle Cell Disease Association of America Inc.","isPartOf":{"@id":"https:\/\/www.sicklecelldisease.org\/#website"},"datePublished":"2021-12-23T16:28:59+00:00","dateModified":"2021-12-29T21:05:39+00:00","author":{"@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/22ff615054be6fdd3e861004652dd8e3"},"breadcrumb":{"@id":"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sicklecelldisease.org\/2021\/12\/23\/scdaa-news-advisory-partial-hold-on-gene-therapy-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sicklecelldisease.org\/"},{"@type":"ListItem","position":2,"name":"SCDAA News Advisory: Partial Hold on Gene Therapy Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.sicklecelldisease.org\/#website","url":"https:\/\/www.sicklecelldisease.org\/","name":"Sickle Cell Disease Association of America Inc.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sicklecelldisease.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/22ff615054be6fdd3e861004652dd8e3","name":"Emma Day","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sicklecelldisease.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/61d0c1099d251a9cdc20252cca50e230?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/61d0c1099d251a9cdc20252cca50e230?s=96&d=mm&r=g","caption":"Emma Day"},"url":"https:\/\/www.sicklecelldisease.org\/author\/emma\/"}]}},"_links":{"self":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts\/5588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/comments?post=5588"}],"version-history":[{"count":3,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts\/5588\/revisions"}],"predecessor-version":[{"id":5591,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/posts\/5588\/revisions\/5591"}],"wp:attachment":[{"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/media?parent=5588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/categories?post=5588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sicklecelldisease.org\/wp-json\/wp\/v2\/tags?post=5588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}